CN1136895C - Medicine for treating coronary heart disease - Google Patents
Medicine for treating coronary heart disease Download PDFInfo
- Publication number
- CN1136895C CN1136895C CNB011194138A CN01119413A CN1136895C CN 1136895 C CN1136895 C CN 1136895C CN B011194138 A CNB011194138 A CN B011194138A CN 01119413 A CN01119413 A CN 01119413A CN 1136895 C CN1136895 C CN 1136895C
- Authority
- CN
- China
- Prior art keywords
- vitamin
- medicine
- heart disease
- coronary heart
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 8
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 8
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 8
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 8
- 239000011718 vitamin C Substances 0.000 claims abstract description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 7
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 7
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002477 riboflavin Drugs 0.000 claims abstract description 7
- 229960003495 thiamine Drugs 0.000 claims abstract description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 7
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 7
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 7
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 7
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 7
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 7
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- FAPWYRCQGJNNSJ-UHFFFAOYSA-L Calcium DL-pantothenate Chemical compound [Ca+2].OCC(C)(C)C(O)C(=O)NCCC([O-])=O.OCC(C)(C)C(O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UHFFFAOYSA-L 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 5
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 206010003119 arrhythmia Diseases 0.000 abstract description 4
- 230000006793 arrhythmia Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 206010033557 Palpitations Diseases 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 abstract 1
- 229960002079 calcium pantothenate Drugs 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating coronary disease. The medicine is prepared by compounding vitamin C, vitamin B1, vitamin B2, vitamin B6, nicotinamide, calcium pantothenate, red sage root, borneol and notoginseng to regulate and accelerate internal metabolism to achieve the goal of treating coronary disease. The medicine can be also used for adjuvant therapy of high blood pressure, presenility, light obesity, etc. The medicine has obvious therapeutic effects on symptoms such as palpitation, short breath, angina pectoris, arrhythmia, etc., caused by coronary disease. Moreover, the medicine has low cost. The total effective rate of the medicine can reach 90.1%.
Description
The present invention relates to a kind of medicine for the treatment of coronary heart disease.
The coronary heart disease shape atherosclerosis that wins again, its cause of disease is because some can not infilter blood-lipoids material such as cholesterol, the triglyceride etc. of arterial wall, be deposited on and form " atheromatous plaque " on the endarterium, the back is because of calmness calcareous in the blood, make original whippy tremulous pulse hardening, along with the atheromatous plaque scope on the endarterium strengthens, cause lumen of vessels to narrow down even block, cause myocardial ischemia, anoxia or necrosis; At present, the medicament categories of treatment coronary heart disease is various, but all is difficult to reach fully the effect of curing, and most drug can only play single, isolated drug effects such as first aid alleviation, heart tonifying rule, blood pressure lowering, just cures the symptoms, not the disease.
It is good to the purpose of this invention is to provide a kind of therapeutic effect, cure rate height, the medicine of the treatment coronary heart disease that cost is low.
Technical scheme of the present invention is:
A kind of medicine for the treatment of coronary heart disease is characterized in that this medicine is to be formed by following material combination:
Radix Salviae Miltiorrhizae extractum 40-70% Borneolum Syntheticum 5-25%
Radix Notoginseng 5-25% vitamin C 6-10%
Vitamin B1 0.5-2% vitamin B2 0.1-2%
Vitamin B6 0.05-1% nicotiamide 2-6%
Racemic calcium pantothenate 0.5-2%
Said ratio by weight percentage.
Above-mentioned Radix Salviae Miltiorrhizae extractum 100 grams are equivalent to the former medicine of 750 grams.
Treatment mechanism of the present invention is:
Find according to relevant medical research, multiple factors such as the Developmental and Metabolic Disorder of atherosclerotic formation and lipid material, endocrine disturbance, hypertension are relevant, these factors cause that finally the concentration of cholesterol in the blood, triglyceride raises, thereby cause the generation of coronary heart disease, therefore the metabolism that adds excitometabolic, especially lipid material is the key of treatment coronary heart disease; Liver is the metabolic center of human body, almost participate in the metabolic process of all substances in the body, thereby, the present invention satisfies the needs of liver to various nutrient substance, especially ascorbic needs to greatest extent from the angle of " protect the liver, treating the liver ", be beneficial to the reparation and the regeneration of liver, promote the recovery of liver metabolism function, thereby accelerate metabolism, reach the purpose of treatment coronary heart disease.
The used vitamin C of the present invention is to the body action range and can promote conversion, metabolism and the drainage of cholesterol, prevents the infiltration of fat to liver, kidney; Vitamin B complex provides the precursor substance of methyl, is the important component of synthetic choline, choline with accumulate in the liver and intravital lipid effect, become the lecithin of easy absorption, have the fat of becoming effect; Niacinamide usp is nadide, coenzyme II constituent, plays hydrogenation, dehydrogenation in biological oxidation, has the metabolic effect of quickening; Racemic calcium pantothenate can participate in constituting coenzyme A, can promote sugar, fat and proteinic metabolism.Above-mentioned all kinds of material not only participates in the metabolism of lipoid material in the liver, also participate in the metabolism of lipid material in the body, be equipped with Radix Salviae Miltiorrhizae, Radix Notoginseng, Borneolum Syntheticum etc. again and have blood circulation promoting and blood stasis dispelling, anticoagulant, prevent thrombosis, triglyceride reducing, blood vessel dilating, acceleration blood flow speed, the medicine of microcirculation improvement, thus make it more can eliminate atherosclerotic plaque effectively, reach the purpose of treatment coronary heart disease; Advantage of the present invention is: 1) had palpitation, breathed hard, symptom such as angina pectoris, arrhythmia coronary heart disease shows, and evident in efficacy; 2) cure rate height, its effective percentage can reach 90.1%; 3) cost is low, and the raw material that the present invention is used all is a raw material commonly used, low price.
Drug main of the present invention will be used for the treatment of coronary heart disease, can play the effect of Comprehensive Treatment.
Medicine of the present invention also can be used for auxiliary treatment hypertension, senilism, slight obesity etc., especially for treatment hypertension certain curative effect is arranged, and is 55 people as the clinical trial case load, and its effective percentage reaches more than 90%.
Medicine of the present invention is made with the method for preparing tablet commonly used, every tablet 0.5 gram, every day three times, each three.
Symptoms such as this medicine is clinical practice 121 examples, and all cases all show angina pectoris, arrhythmia, cardiopalmus that coronary heart disease has, breathe hard, and through making a definite diagnosis, below for the curative effect statistics of following up a case by regular visits to record is arranged.
Criterion of therapeutical effect:
Cure---after treatment, asymptomatic more than 2 years;
Produce effects---the symptom that is shown has and obviously weakens;
Effectively---with not the treatment before sx;
Invalid---with symptom indifference before the treatment.
The curative effect statistics:
| Symptom | Case load | Therapeutic outcome | |||||||
| Cure | ％ | Produce effects | ％ | Effectively | ％ | Invalid | ％ | ||
| Cardiopalmus | 38 | 6 | 15.6 | 14 | 36.8 | 15 | 39.5 | 3 | 8.0 |
| Breathe hard | 34 | 8 | 23.5 | 11 | 32.4 | 13 | 38.2 | 2 | 5.9 |
| Arrhythmia | 22 | 5 | 22.7 | 8 | 36.4 | 5 | 22.7 | 4 | 18.2 |
| Angina pectoris (gently) | 12 | 4 | 33.3 | 4 | 33.3 | 3 | 25.0 | 1 | 8.4 |
| Angina pectoris (in) | 10 | 2 | 20.0 | 4 | 40.0 | 3 | 30.0 | 1 | 10.0 |
| Old myocardial infarction | 5 | 2 | 40.0 | 2 | 40.0 | 1 | 20.0 | ||
| Amount to | 121 | 25 | 20.7 | 43 | 35.5 | 41 | 33.9 | 12 | 9.9 |
From above-mentioned statistical table as can be seen, the total effective rate of the medicine of this treatment coronary heart disease is 90.1%.
Embodiment 1:
Get the raw material (unit is gram) of following weight:
Radix Salviae Miltiorrhizae extractum 40.0g Borneolum Syntheticum 20.0g
Radix Notoginseng 25.0g vitamin C 6.0g
Vitamin B1 2.0g vitamin B2 2.0g
Vitamin B6 1.0g nicotiamide 2.0g
Racemic calcium pantothenate 2.0g
The method that above-mentioned raw materials is made tablet according to routine is made tablet, every 0.5 gram.
Embodiment 2:
Get the raw material (unit is gram) of following weight:
Radix Salviae Miltiorrhizae extractum 70.0g Borneolum Syntheticum 5.0g
Radix Notoginseng 5.0g vitamin C 10.0g
Vitamin B1 1.5g vitamin B2 1.0g
Vitamin B6 0.5g nicotiamide 6.0g
Racemic calcium pantothenate 1.0g
The method that above-mentioned raw materials is made tablet according to routine is made tablet, every 0.5 gram.
Embodiment 3:
Get the raw material (unit is gram) of following weight:
Radix Salviae Miltiorrhizae extractum 57.9g Borneolum Syntheticum 14.5g
Radix Notoginseng 14.5g vitamin C 8.69g
Vitamin B1 0.58g vitamin B2 0.29g
Vitamin B6 0.06g nicotiamide 2.9g
Racemic calcium pantothenate 0.58g
The method that above-mentioned raw materials is made tablet according to routine is made tablet, every 0.5 gram.
Claims (2)
1. medicine for the treatment of coronary heart disease is characterized in that this medicine is to be formed by following material combination:
Radix Salviae Miltiorrhizae extractum 40-70% Borneolum Syntheticum 5-25%
Radix Notoginseng 5-25% vitamin C 6-10%
Vitamin B1 0.5-2% vitamin B2 0.1-2%
Vitamin B6 0.05-1% nicotiamide 2-6%
Racemic calcium pantothenate 0.5-2% said ratio by weight percentage.
2. according to the described medicine of claim 1, it is characterized in that: the above-mentioned raw materials proportioning is,
Radix Salviae Miltiorrhizae extractum 57.9% Borneolum Syntheticum 14.5%
Radix Notoginseng 14.5% vitamin C 8.69%
Vitamin B1 0.58% vitamin B2 0.29%
Vitamin B6 0.06% nicotiamide 2.9%
Racemic calcium pantothenate 0.58% said ratio by weight percentage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011194138A CN1136895C (en) | 2001-05-24 | 2001-05-24 | Medicine for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011194138A CN1136895C (en) | 2001-05-24 | 2001-05-24 | Medicine for treating coronary heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1325725A CN1325725A (en) | 2001-12-12 |
| CN1136895C true CN1136895C (en) | 2004-02-04 |
Family
ID=4663638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011194138A Expired - Fee Related CN1136895C (en) | 2001-05-24 | 2001-05-24 | Medicine for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1136895C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486464B2 (en) | 2000-12-22 | 2013-07-16 | Tasly Pharmaceutical Group Co. Ltd. | Herbal composition for angina pectoris, method to prepare same and uses thereof |
| US20050037094A1 (en) | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
| RU2275196C2 (en) * | 2004-07-26 | 2006-04-27 | Михаил Викторович Котельников | Method for treating acute coronary thrombosis cases |
| GB0703514D0 (en) * | 2007-02-23 | 2007-04-04 | Univ Ulster | Use of riboflavin |
| CN107050107A (en) * | 2016-12-29 | 2017-08-18 | 李富雄 | A kind of composition of medicine for coordinating treatment hypertension |
-
2001
- 2001-05-24 CN CNB011194138A patent/CN1136895C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1325725A (en) | 2001-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1136895C (en) | Medicine for treating coronary heart disease | |
| CN1267119C (en) | Medication for curing skin disease | |
| CN1504208A (en) | Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease | |
| CN1239194C (en) | Chinese patent medicine for treating coronary heart disease and angina pectoris | |
| CN1923227A (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1171943A (en) | Chinese medicinal preparation for treating heart disease | |
| CN1068043C (en) | Ginkgo leaf liquor and preparation process | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN1149096C (en) | Medicine for treating drug-fast tuberculosis | |
| CN1117848A (en) | Application of "Wujinshi" (a Chinese medicine) effective component in medicines with invigerating blood-circulation and regulating cell function | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN100335099C (en) | Externally applied pure Chinese medicinal tincture for treating manus and pedes tinea | |
| CN1265829C (en) | Healthy product for preventing and treating cardiovascular and cerebrovascular disease | |
| CN1883553A (en) | A pharmaceutical composition for preventing and treating coronary heart disease and angina pectoris and method for preparing same | |
| CN101040920A (en) | Drug for curing nephrosis and its preparing method | |
| CN1754546A (en) | A kind of traditional Chinese medicine preparation for treating and preventing diabetes and its vascular disease | |
| CN1202857C (en) | Medicinal pill for treating gastritis and its producing process | |
| CN100337677C (en) | Cassia oil composition and its application in making medicine | |
| CN1328829A (en) | Medicine for curing angiocardiopathy | |
| CN1965933A (en) | Medicated tea for lowering blood pressure and method for preparing same | |
| CN1942180A (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
| CN1481891A (en) | Medication for chronic renal failure | |
| CN1459293A (en) | Traditional Chinese medicine for treating prolapse of lumbar intervertebral disc and osteoproliferation | |
| CN1330930A (en) | Medicine for treating cardiovascular disease | |
| CN1548061A (en) | Mongolian medicine for treating coronary heart disease and angina pectoris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |